

Claire Paquet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3483988/publications.pdf>

Version: 2024-02-01

118
papers

3,190
citations

186265

28
h-index

182427

51
g-index

134
all docs

134
docs citations

134
times ranked

3954
citing authors

#	ARTICLE	IF	CITATIONS
1	Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. <i>Journal of Neurology</i> , 2022, 269, 44-46.	3.6	127
2	Is there a link between headache and cognitive disorders? A systematic review. <i>Revue Neurologique</i> , 2022, 178, 285-290.	1.5	1
3	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	9.0	38
4	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. <i>EBioMedicine</i> , 2022, 75, 103793.	6.1	4
5	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848.	7.6	20
6	Biomarqueurs de la maladie d'Alzheimer: des avancées très rapides. <i>La Presse Médicale Formation</i> , 2022, , .	0.1	0
7	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 525-530.	2.6	3
8	Cognitive decline and brainstem hypometabolism in long COVID: A case series. <i>Brain and Behavior</i> , 2022, 12, e32513.	2.2	29
9	Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, A β 42, and A β 40 in Probable Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 791-802.	2.6	10
10	Using virtual reality in lumbar puncture training improves students learning experience. <i>BMC Medical Education</i> , 2022, 22, 244.	2.4	7
11	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
12	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12314.	2.4	15
13	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	12
14	High-sensitivity quantification of acetylcholine and choline in human cerebrospinal fluid with a validated LC-MS/MS method. <i>Talanta</i> , 2021, 224, 121881.	5.5	9
15	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.8	81
16	Positive effects of lumbar puncture simulation training for medical students in clinical practice. <i>BMC Medical Education</i> , 2021, 21, 18.	2.4	13
17	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 561-565.	2.4	8
18	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3136.	4.1	17

#	ARTICLE	IF	CITATIONS
19	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. <i>Diagnostics</i> , 2021, 11, 754.	2.6	7
20	Brain Glucose Metabolism in Cerebral Amyloid Angiopathy. <i>Stroke</i> , 2021, 52, 1478-1482.	2.0	3
21	Association of sleep duration in middle and old age with incidence of dementia. <i>Nature Communications</i> , 2021, 12, 2289.	12.8	254
22	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 60, e13-e17.	2.3	0
23	Determinants of Post-Operative Cognitive Decline in Elderly People. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-7.	2.7	3
24	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1439-1446.	2.6	2
25	The Diagnostic Value of a Short Memory Test: The TNI-93. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-11.	2.6	1
26	Alcohol misuse can mimic frontotemporal degeneration in Alzheimer's disease patients. <i>Revue Neurologique</i> , 2021, , .	1.5	0
27	Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. <i>Frontiers in Nutrition</i> , 2021, 8, 807970.	3.7	17
28	Telemedicine in French memory clinics during Covid-19 crisis. <i>Alzheimer's and Dementia</i> , 2021, 17, e052037.	0.8	0
29	Long-term cognitive and motor decline across the spectrum of Lewy body disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
30	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	7
31	Plasma p-tau231 in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A β 2 pathology and preclinical application. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
32	Hyperuricemia, Gout, and the Brain: an Update. <i>Current Rheumatology Reports</i> , 2021, 23, 82.	4.7	17
33	Bright light therapy improved sleep disturbances in a patient with dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2020, 20, 124-125.	1.2	4
34	Dose-dependent neuroprotective effect of the JNK inhibitor Brimipitide in 5xFAD transgenic mice. <i>Brain Research</i> , 2020, 1727, 146587.	2.2	6
35	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	6.2	20
36	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. <i>Immunology Letters</i> , 2020, 228, 129-134.	2.5	38

#	ARTICLE	IF	CITATIONS
37	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	8.4	39
38	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	6.2	7
39	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037097.	0.8	0
40	In vivo characterization of progressive amnesic syndrome due to suspected neurodegenerative non-Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039587.	0.8	0
41	STAT3 inhibition reverses neuroinflammation and $\text{A}\beta^2$ metabolism induced by systemic inflammation. <i>Alzheimer's and Dementia</i> , 2020, 16, e041019.	0.8	4
42	Memory assessment in illiterate patients: The diagnostic value of the TNI 93. <i>Alzheimer's and Dementia</i> , 2020, 16, e042059.	0.8	0
43	Association of Alzheimer's disease and amyotrophic lateral sclerosis: A series of cases and review of the literature. <i>Alzheimer's and Dementia</i> , 2020, 16, e045814.	0.8	0
44	Blood-based detection of early-stage Alzheimer using multiomics and machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, e047334.	0.8	0
45	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 903-911.	2.6	9
46	Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. <i>Revue Neurologique</i> , 2020, 176, 677-683.	1.5	9
47	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.1	50
48	Diagnostic prÃ©coce et biomarqueurs biologiques de la maladie d'Alzheimer. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2020, 20, 120S7-120S10.	0.2	0
49	Title is missing!. , 2020, 17, e1003289.		0
50	Title is missing!. , 2020, 17, e1003289.		0
51	Title is missing!. , 2020, 17, e1003289.		0
52	Title is missing!. , 2020, 17, e1003289.		0
53	Title is missing!. , 2020, 17, e1003289.		0
54	Title is missing!. , 2020, 17, e1003289.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 17, e1003289.		0
56	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	1.9	16
57	Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice. <i>Clinica Chimica Acta</i> , 2019, 495, 451-456.	1.1	13
58	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380.	1.9	17
59	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β -amyloid peptide and tau. <i>PLoS ONE</i> , 2019, 14, e0217026.	2.5	18
60	Frontotemporal dementia is the leading cause of τ /T+ profiles defined with $A\beta_{42/40}$ ratio. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 161-169.	2.4	8
61	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. <i>Aging Cell</i> , 2019, 18, e12887.	6.7	28
62	CSF level of β -amyloid peptide predicts mortality in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 29.	6.2	19
63	O20501: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P545.	0.8	2
64	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144.	2.3	25
65	Could ryanodine receptor dysfunction be linked to PKR brain accumulations in Alzheimer's disease?. <i>Medical Hypotheses</i> , 2018, 113, 45.	1.5	1
66	Downregulated apoptosis and autophagy after anti- $A\beta$ immunotherapy in Alzheimer's disease. <i>Brain Pathology</i> , 2018, 28, 603-610.	4.1	24
67	O31406: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1061.	0.8	0
68	P1092: NEUROPROTECTIVE EFFECTS OF PKR KNOCKOUT IN 5XFAD ALZHEIMER MICE AND NEURON-MICROGLIA CO-CULTURES. <i>Alzheimer's and Dementia</i> , 2018, 14, P306.	0.8	0
69	P3249: COMBINING MATHEMATICAL MODEL AND CATECHOLAMINE QUANTIFICATIONS TO SCREEN ALZHEIMER DISEASE FROM A SIMPLE BLOOD TEST. <i>Alzheimer's and Dementia</i> , 2018, 14, P1168.	0.8	0
70	Blood-Based Kinase Assessments in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 338.	3.4	11
71	P2277: CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P784.	0.8	0
72	Brimapitide Reduced Neuronal Stress Markers and Cognitive Deficits in 5XFAD Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 665-674.	2.6	10

#	ARTICLE	IF	CITATIONS
73	Increased PKR level in human CADASIL brains. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 771-774.	2.8	1
74	Relevance of A β 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	3.4	59
75	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 889-897.	2.6	9
76	Biomarqueurs du liquide c \acute{e} rebrospinal dans la maladie d \acute{e} Alzheimer. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 307-320.	0.0	1
77	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
78	Effect of anti-cancer drugs on microglia in patient-derived breast cancer xenografted mouse models. <i>Neuropathology</i> , 2017, 37, 91-93.	1.2	4
79	PKR involvement in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 83.	6.2	52
80	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 905-913.	2.6	21
81	Dual Kinase Inhibition Affords Extended in Vitro Neuroprotection in Amyloid- β Toxicity. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1659-1670.	2.6	11
82	Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1411-1418.	2.6	12
83	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1459-1471.	2.6	28
84	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	6.2	121
85	Seizures in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2016, 87, 912-919.	1.1	81
86	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 27.	6.2	18
87	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.8	179
88	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. <i>European Journal of Human Genetics</i> , 2016, 24, 710-716.	2.8	77
89	Neuroinflammation and A β Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. <i>Scientific Reports</i> , 2015, 5, 8489.	3.3	70
90	Cerebrospinal fluid amyloid- β 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30.	6.2	101

#	ARTICLE	IF	CITATIONS
91	Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 168.	2.4	10
92	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. <i>Cortex</i> , 2015, 65, 89-101.	2.4	19
93	PKR downregulation prevents neurodegeneration and β -amyloid production in a thiamine-deficient model. <i>Cell Death and Disease</i> , 2015, 6, e1594-e1594.	6.3	32
94	Effect of amyloid β ($A\beta$) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK-3 β). <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 445-457.	3.2	17
95	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 151-161.	2.4	75
96	Nepriylsin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. <i>European Heart Journal</i> , 2015, 36, 902-905.	2.2	61
97	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. <i>Alzheimer's and Dementia</i> , 2015, 11, 1125-1126.	0.8	8
98	Effect of active $A\beta$ immunotherapy on neurons in human Alzheimer's disease. <i>Journal of Pathology</i> , 2015, 235, 721-730.	4.5	31
99	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38.	6.2	44
100	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
101	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. <i>Journal of Neurology</i> , 2014, 261, 144-151.	3.6	56
102	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 857-861.	2.6	22
103	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <i>Journal of Neurology</i> , 2014, 261, 1187-1195.	3.6	11
104	Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 611-616.	2.6	9
105	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <i>Neurobiology of Disease</i> , 2013, 54, 486-491.	4.4	14
106	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 406-413.	0.8	63
107	Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. <i>HIV Medicine</i> , 2013, 14, 311-315.	2.2	29
108	Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 297-305.	2.6	51

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. PLoS ONE, 2013, 8, e53587.	2.5	46
110	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 γ pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 885-896.	3.8	139
111	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. BMC Neuroscience, 2012, 13, 84.	1.9	8
112	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52
113	The PKR Activator PACT Is Induced by A β ² : Involvement in Alzheimer's Disease. Brain Pathology, 2012, 22, 219-229.	4.1	40
114	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. Brain Pathology, 2011, 21, 189-200.	4.1	55
115	Biogenesis and regulation of microRNA: implication in Alzheimer's disease. Future Neurology, 2010, 5, 839-850.	0.5	2
116	A cortical form of CADASIL with cerebral A β ² amyloidosis. Acta Neuropathologica, 2010, 120, 813-820.	7.7	14
117	Could PKR inhibition modulate human neurodegeneration?. Expert Review of Neurotherapeutics, 2009, 9, 1455-1457.	2.8	20
118	Neuronal Phosphorylated RNA-Dependent Protein Kinase in Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 190-198.	1.7	29